AstraZeneca, Amgen Phase 3 Asthma Treatment Trial Meets Primary Endpoint -- Update
November 10 2020 - 7:46AM
Dow Jones News
By Sabela Ojea and Colin Kellaher
AstraZeneca PLC and Amgen Inc. on Tuesday said a Phase 3 trial
of tezepelumab, a potential treatment for patients with severe,
uncontrolled asthma, met its key goals.
The companies said the study met its primary endpoint of
statistically significant and clinically meaningful reduction in
exacerbations in a broad population of patients with severe
asthma.
The trial also met the primary endpoint in a group of patients
with low levels of eosinophils, a type of white blood cell, the
companies said, adding that tezepelumab was very well tolerated in
patients with severe asthma.
U.K. pharmaceutical giant AstraZeneca and Amgen, a Thousand
Oaks, Calif., biotechnology company, agreed in 2012 to collaborate
on tezepelumab, which the companies said has the potential to treat
a broad population of severe asthma patients regardless of their
type of inflammation.
Under an update earlier this year to their collaboration, Amgen
and AstraZeneca will continue to share costs and profits equally
after payment by AstraZeneca of a mid-single-digit royalty to
Amgen. AstraZeneca continues to lead development of the drug, while
Amgen continues to lead manufacturing.
Write to Sabela Ojea at sabela.ojea@wsj.com and Colin Kellaher
at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 10, 2020 07:31 ET (12:31 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Apr 2024 to May 2024
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From May 2023 to May 2024
